NDI Notification Guidance Deadline Included In Senate Draft Bill For FDA User Fee Programs
Executive Summary
HELP Committee Chairwoman Patty Murray, and ranking member Richard Burr also include supplement registration requirement in discussion draft for reauthorizing FDA’s user fee programs for prescription, generic and biosimilar drugs and medical devices.
You may also be interested in...
Protection For NDIs Bigger Concern In US Than Giving More Time For Notifications, CRN Contends
FDA should protect companies which “do the right thing” by submitting new dietary ingredient notifications, CRN's Steve Mister said during FDLI's annual conference.
No Longer Draft, Senate Mandatory Supplement Registration Bill Gets Flood Of Opposition
Some stakeholders have supported mandatory listing but they join opponents questioning legislation also authorizing FDA to prohibit sales of products compliant with manufacturing and labeling regulations but deficient, incomplete or late with registration information required for the agency.
By Requiring Pre-Market Listing, US FDA Could ‘Just Say No’ To Some Dietary Supplements – NPA
Proposal “seems driven by a desire to allow FDA to ‘bar the door’ from listing anything that they wish to keep out that doesn’t meet their convenience,” NPA CEO Daniel Fabricant tells Senate HELP Committee.